Viewing Study NCT03459534


Ignite Creation Date: 2025-12-25 @ 2:30 AM
Ignite Modification Date: 2025-12-26 @ 1:06 AM
Study NCT ID: NCT03459534
Status: RECRUITING
Last Update Posted: 2024-10-28
First Post: 2018-02-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Sponsor: Il-Yang Pharm. Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module